intoxicant.wiki2catechol4school
Compound

Rolipram

Also called Adeo

Original Wikipedia articleen.wikipedia.org/wiki/Rolipram revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Part of the metabolic pathway of Rolipram. See the timeline on the metabolic highway.

Enzymes that break it down: CYP2C8, CYP2C9, CYP2C19 and CYP2D6. Wikipedia’s drug infobox says: “Liver via CYP2C8, CYP2C9, CYP2C19 and CYP2D6” (revision 1329367371).

Overview

Rolipram is a selective phosphodiesterase-4 inhibitor discovered and developed by Schering AG as a potential antidepressant drug in the early 1990s. It served as a prototype molecule for several companies' drug discovery and development efforts. Rolipram was discontinued after clinical trials showed that its therapeutic window was too narrow; it could not be dosed at high enough levels to be effective without causing significant gastrointestinal side effects.[1][2] WP

Rolipram has several activities that make it a continuing focus for research. The etiology of many neurodegenerative diseases involves misfolded and clumped proteins which accumulate in the brain. Cells have a mechanism to dispose of such proteins called the proteasome. However, in Alzheimer's disease and some other conditions the activity of these proteasomes is impaired leading to a buildup of toxic aggregates. Research in mice suggests that rolipram has the ability to ramp up the activity of proteasomes and reduce the burden of these aggregates. Preliminary evidence suggests that this can improve spatial memory in mice engineered to have aggregate build-up. Rolipram continues to be used in research as a well-characterized PDE4 inhibitor. It has been used in studies to understand whether PDE4 inhibition could be useful in autoimmune diseases, Alzheimer's disease, cognitive enhancement, spinal cord injury, and respiratory diseases like asthma and COPD.[2–8] WP

Chemistry

Formula
C16H21NO3 PC
CAS number
61413-54-5 PC
Molar mass (g/mol)
275.34 PC
IUPAC name (computed by PubChem)
4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one PC
SMILES
COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3 PC
InChIKey
HJORMJIFDVBMOB-UHFFFAOYSA-N PC
PubChem CID
5092
IUPAC name
(RS)-4-(3-cyclopentyloxy-4-methoxy-phenyl)pyrrolidin-2-one WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

Awaiting sourceChecked against PsychonautWiki and TripSit as each pull runs. This box is replaced as soon as a source has data.

User reports

Erowid erowid.org

Listings
Awaiting sourceExperience Vault listing and report categories.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Bluelight bluelight.org

Listings
Awaiting sourceTrip report threads and this substance's discussion forum.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Reddit reddit.com

Listings
Awaiting sourceTrip report posts and the relevant subreddits.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

Sources

  1. Journal / agency Zhu J, Mix E, Winblad B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Reviews. Winter 2001. doi:10.1111/j.1527-3458.2001.tb00206.x · PMID 11830756 · PMC6741679
  2. Other McKenna JM, Muller GW. Cyclic Nucleotide Phosphodiesterases in Health and Disease. December 2006
  3. Journal / agency Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, Duff KE. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nature Medicine. January 2016. doi:10.1038/nm.4011 · PMID 26692334 · PMC4787271
  4. Journal / agency Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Medicine. April 2013. doi:10.1186/1741-7015-11-96 · PMID 23557064 · PMC3616808
  5. Journal / agency García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chemical Neuroscience. November 2012. doi:10.1021/cn3000907 · PMID 23173065 · PMC3503343
  6. Journal / agency Normann C, Berger M. Neuroenhancement: status quo and perspectives. European Archives of Psychiatry and Clinical Neuroscience. November 2008. doi:10.1007/s00406-008-5022-2 · PMID 18985306
  7. Journal / agency Hannila SS, Filbin MT. The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Experimental Neurology. February 2008. doi:10.1016/j.expneurol.2007.06.020 · PMID 17720160 · PMC2692909
  8. Journal / agency Huang Z, Mancini JA. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Current Medicinal Chemistry. 2006. doi:10.2174/092986706778773040 · PMID 17168849

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.